[
    [
        {
            "time": "",
            "orginal_text": "金域医学：国开博裕计划减持不超过2.56%股份 拟减持股份",
            "features": {
                "keywords": [
                    "金域医学",
                    "国开博裕",
                    "减持",
                    "2.56%"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "金域医学：国开博裕计划减持不超过2.56%股份 拟减持股份",
            "scores": {
                "News_content": "金域医学：国开博裕计划减持不超过2.56%股份 拟减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "金域医学(603882.SH)：国开博裕拟清仓减持不超2.56%的股份 拟减持股份",
            "features": {
                "keywords": [
                    "金域医学",
                    "国开博裕",
                    "清仓减持",
                    "2.56%"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "金域医学(603882.SH)：国开博裕拟清仓减持不超2.56%的股份 拟减持股份",
            "scores": {
                "News_content": "金域医学(603882.SH)：国开博裕拟清仓减持不超2.56%的股份 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业11月月报暨三季报总结：三季报医药整体表现良好 当前时点重点关注Q3业绩超预期的疫苗、CXO、医疗服务、零售药店等板块",
            "features": {
                "keywords": [
                    "医药生物",
                    "三季报",
                    "业绩超预期",
                    "疫苗",
                    "CXO",
                    "医疗服务",
                    "零售药店"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗",
                    "CXO",
                    "医疗服务",
                    "零售药店"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药生物行业11月月报暨三季报总结：三季报医药整体表现良好 当前时点重点关注Q3业绩超预期的疫苗、CXO、医疗服务、零售药店等板块",
            "scores": {
                "News_content": "医药生物行业11月月报暨三季报总结：三季报医药整体表现良好 当前时点重点关注Q3业绩超预期的疫苗、CXO、医疗服务、零售药店等板块",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]